📰 globenewswire.com/news-relea… Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements 🔹Both previously disclosed Nasdaq compliance matters are now closed $TVGN @Nasdaq #Compliance

📰 globenewswire.com/news-relea… Tevogen is a healthcare enterprise focused on improving the affordability and accessibility of life-saving medicines. The Company brings together three complementary efforts: @TevogenBio, its biotechnology initiative; @TevogenAI, its artificial intelligence and technology initiative; and @TevogenHS its healthcare services, its emerging healthcare services initiative. Together, these efforts are designed to create a more integrated healthcare model in which science, technology, and operational efficiency work together to reduce the cost of medication and expand patient access. “We are not simply building a biotechnology company. We are building a healthcare enterprise,” said @DrRyanSaadi, MD, MPH, Founder and Chief Executive Officer of Tevogen. #TVGN

Tevogen Bio Announces 2026 Annual Meeting of Stockholders 📰 globenewswire.com/news-relea… The Annual Meeting will be held virtually. Stockholders of record as of July 23, 2026 will be entitled to receive notice of and vote at the Annual Meeting or any adjournment thereof. $TVGN

📰 globenewswire.com/news-relea… “Tevogen’s evaluation of potential MSO and CRO acquisitions reflects a disciplined approach to building revenue-generating capabilities that may support long-term financial self-sufficiency,” said Kirti Desai, Chief Financial Officer at Tevogen. “With approximately $100 million in potential combined annual revenue under evaluation, we believe these opportunities could represent an important step toward strengthening the Company’s financial foundation while remaining aligned with our mission to make healthcare more affordable and accessible.” $TVGN #HealthcareEnterprise #StrategicAcquisitions #Revenue @DrRyanSaadi

“Bridging medical science and artificial intelligence to develop affordable, lifesaving therapies isn’t just innovation, it’s the future of medicine.” - Ryan Saadi, @CEO_TEVOGEN_BIO $TVGN #JPMorganHealthcareConference #affordable #accessible #celltherapy #ICYMI

At JPM43 Mittul Mehta, @Head_TevogenAI and @drhew Chief Medical Officer & VP of Healthcare at @Microsoft discussed AI in Biopharma: Next Frontier of Medical Innovation $TVGN $MSFT @DrRyanSaadi #Healthcare #ArtificialIntelligence #AI #Innovation #ICYMI

📰 globenewswire.com/news-relea… “Advancing PredicTcell toward completion marks an important milestone in our AI strategy,” said @Head_TevogenAI Mittul Mehta, “As we begin exploring commercial pathways, our focus remains on maintaining scientific rigor while building scalable tools that can extend the impact of our platform beyond internal use.” $TVGN #PredicTcell #ArtificialIntelligence #MachineLearning #DrugDiscovery #Immunotherapy

🔗 databricks.com/blog/tevogen-… As part of our ongoing work on PredicTcell™, we’ve been leveraging scalable data infrastructure to process and analyze hundreds of millions of peptide sequences across diverse disease areas. This recent feature by @databricks highlights elements of that journey, how modern data architecture can support complex biological modeling and help move from static datasets toward adaptive, continuously learning systems. Thank you, Databricks, for supporting @TevogenAI’s journey toward what we consider the “holy grail”: 𝘵𝘩𝘦 𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘵𝘰 𝘱𝘳𝘦𝘥𝘪𝘤𝘵 𝘵𝘩𝘦 𝘱𝘳𝘰𝘵𝘦𝘰𝘮𝘦 𝘧𝘰𝘳 𝘢𝘯𝘺 𝘨𝘪𝘷𝘦𝘯 𝘤𝘰𝘮𝘣𝘪𝘯𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘱𝘳𝘰𝘵𝘦𝘪𝘯 𝘢𝘯𝘥 𝘏𝘓𝘈 𝘵𝘺𝘱𝘦. $TVGN #ArtificialIntelligence #MachineLearning #Bioinformatics #DataEngineering #AIinHealthcare

Tevogen.AI at @FABConSQLCon Tevogen CIO and @Head_TevogenAI, Mittul Mehta, speaking to building an AI-ready data foundation to power precision immunotherapy, transforming complex scientific data spanning millions of protein sequences and hundreds of millions of peptides. $TVGN $MSFT #AI #Biotech #FabCon #Microsoft #PrecisionMedicine #BigData #Analytics

📰 globenewswire.com/news-relea… @Head_TevogenAI Mittul Mehta, stated, “Our goal is to reduce trial-and-error in immunotherapy design and ultimately predict the proteome for any given combination of protein and HLA type. As our prediction quality improves, we believe we can meaningfully increase success rates while lowering development risk. That combination has the potential to create significant long-term value.” @TevogenAI $TVGN #PredicTcell #artificialintelligence #DrugDiscovery #immunotherapy

📢 From Mittul Mehta, Tevogen CIO and @Head_TevogenAI. Most companies celebrate going public. We used it as a starting gun. Two years ago, Tevogen went public at Nasdaq - A day I’ll always remember for the energy, the optimism, and the responsibility that comes with running a public company. Then the morning after, the real work began. When we stood up Tevogen.AI, the conviction was clear: AI wasn't going to be a support function. It was going to be a frontier capability that fundamentally changed how we read, understand, and act on complex biological data. Simple in conviction. Hard in execution. Since then, the teams have gone from thesis to tangible: 655 million unique peptides, models scaling nearly 20x between training cycles, and a platform built to compound as the science advances. None of that came from moving fast for its own sake. It came from disciplined decisions — what to build, what to buy, and where partnerships produced durable leverage. What excites me most isn't what's already been achieved… It's what's next. As we close out beta training for PredicTcell™ and move into AdapTcell™, the platform is transitioning from experimentation to operational reality. The feedback loop between our AI and biology teams is tightening with every cycle and increasing learning velocity. Two years on, the work feels less about celebration and more about momentum, which is exactly where it should be. For leaders building AI at scale: where are you seeing the biggest gap between experimentation and execution? #AIinBiotech #LifeSciences #TechnologyStrategy #Leadership $TVGN #Board #CIO #AIPlatforms #PublicCompany #BoardPerspective #TechnologyLeadership

📰 globenewswire.com/news-relea… “Tevogen began as a T cell therapy biotech and has since evolved into a diversified healthcare company, including a scalable healthcare AI initiative. The Company’s goal is to launch at least four blockbuster products by 2030, and to pursue revenue generation in 2026 through our current programs, potential asset acquisitions, and joint ventures.” - @DrRyanSaadi $TVGN #CorporateGovernance #EquityIncentives #RevenueFocus #GrowthStrategy #HealthcareAI

📢 From Mittul Mehta, Tevogen CIO and Head of @TevogenAI Reflecting on the past year at Tevogen.AI, I’m proud to share a snapshot of what we’ve built, and where we’re headed. Through strategic partnerships with @Databricks and @Microsoft, our team has developed a highly curated dataset spanning ~24 million proteins. Using our proprietary data refinement processes, this has expanded into a library of 655 million unique peptides, with nearly 16 billion data points across 12 clinical conditions and the known human genome. By cross-referencing this work with 37 million expert scientific articles, we’ve been able to enrich our datasets, uncover critical biochemical properties of amino acid chains, identify key anchor residues, and sharpen HLA specificity at scale. On the modeling front, our PredicTcell™ journey has accelerated rapidly. While the alpha model was trained on ~100,000 data points and served as an important benchmark, the beta version now incorporates 1.8 million data points, representing nearly a 20-fold scale-up. As we wrap the PredicTcell™ beta and begin training AdapTcell™, I’m excited to continue sharing progress as Tevogen.AI advances toward what many consider the Holy Grail of immunology: Predicting the proteome for any given protein–HLA combination. More to come. @drhew @hoifungpoon @TevogenAI @Microsoft @databricks $TVGN #TevogenAI #AIinBiotech #ComputationalBiology #Immunology #PrecisionMedicine #MachineLearning

🎙Q&A with Tevogen CEO🎙 Q. As Tevogen continues to build long-term value, how do you think about capital allocation and sharing that success with shareholders over time? A. I’ve always believed that when a company succeeds, shareholders should share in that success. I am supportive of the Board evaluating a potential one-time special cash dividend in the context of future performance, which is obviously subject to Board approval. I personally believe returning capital to shareholders is critical for long term value creation for any high growth enterprise. - @DrRyanSaadi $TVGN #affordable #accessible #celltherapy #JPM2026 @Tevogen @TevogenAI

📰 globenewswire.com/news-relea… 🔹Platform & Manufacturing Progress: Advanced the ExacTcell™ platform in 2025, improving CTL yield, consistency, and throughput while progressing toward in-house GMP manufacturing capabilities. 🔹Pipeline Expansion: Expanded the CTL pipeline across multiple viral and oncology indications, including EBV-associated lymphomas, chronic hepatitis B, and HPV-related cancers, supported by @TevogenAI. 🔹Execution & Value Creation: Achieved key scientific and operational milestones positioning Tevogen as a scalable, multi-program cell therapy organization with a foundation for long-term value creation. $TVGN #affordable #accessible #celltherapy #JPM2026